Charles Swanton

(Robert) Charles Swanton is British physician scientist specialising in oncology and cancer research.

Swanton is a senior group leader at London's Francis Crick Institute, Royal Society Napier Professor in Cancer and thoracic medical oncologist at University College London and University College London Hospitals, co-director of the Cancer Research UK (CRUK) Lung Cancer Centre of Excellence, and Chief Clinician of Cancer Research UK.

Swanton completed was educated at St Paul's School, London and completed his PhD in 1999 at what was then the Imperial Cancer Research Fund Laboratories (now the Francis Crick Institute) and his Cancer Research UK clinician scientist/medical oncology training in 2008.

Swanton combines his laboratory research with clinical duties as co-director of the CRUK Lung Cancer Centre, focussed on how tumours evolve over space and time.

He has helped to define the branched evolutionary histories of solid tumours, processes that drive cancer cell-to-cell variation in the form of new cancer mutations or chromosomal instabilities, and the impact of such cancer diversity on effective immune surveillance and clinical outcome.

Swanton is a co-founder of Achilles Therapeutics with Sergio Quezada, Karl Peggs and Mark Lowdell.

Achilles Therapeutics is a UCL/CRUK and Francis Crick Institute biotechnology company funded by Syncona that develops adoptive T cell therapies targeting clonal/truncal neo-antigens present in every tumour cell to limit drug resistance and tumour evolution.

Swanton is the son of Robert Howard Swanton (MD, FRCP) a consultant cardiologist at UCL.